{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:45:46Z","timestamp":1792791946618,"version":"4.5.0"},"reference-count":361,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018942","name":"Centro Singular de Investigaci\u00f3n de Galicia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018942","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.blre.2026.101385","type":"journal-article","created":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T00:07:09Z","timestamp":1772842029000},"page":"101385","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Ph-chromosome-negative myeloproliferative neoplasms: clonal dynamics are the name of the game"],"prefix":"10.1016","volume":"76","author":[{"given":"Mohammadamin","family":"Noorafrooz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramin","family":"Noorafrooz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Barosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert Peter","family":"Gale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.blre.2026.101385_bb0005","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1182\/blood.2021014668","article-title":"Single-cell methods in myeloproliferative neoplasms: old questions, new technologies","volume":"141","author":"O\u2019Sullivan","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101385_bb0010","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.stem.2018.01.011","article-title":"Clonal Hematopoiesis and Evolution to Hematopoietic Malignancies","volume":"22","author":"Bowman","year":"2018","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.blre.2026.101385_bb0015","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2026.101385_bb0020","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.exphem.2015.06.007","article-title":"Pathogenesis of myeloproliferative neoplasms","volume":"43","author":"Skoda","year":"2015","journal-title":"Exp Hematol"},{"key":"10.1016\/j.blre.2026.101385_bb0025","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1158\/2159-8290.CD-14-0736","article-title":"JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response","volume":"5","author":"Kleppe","year":"2015","journal-title":"Cancer Discov"},{"key":"10.1016\/j.blre.2026.101385_bb0030","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s13045-021-01116-z","article-title":"Molecular pathogenesis of the myeloproliferative neoplasms","volume":"14","author":"Greenfield","year":"2021","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.blre.2026.101385_bb0035","doi-asserted-by":"crossref","first-page":"e438","DOI":"10.3324\/haematol.2015.129510","article-title":"DNMT3A mutations occur early or late in patients with myeloproliferative neoplasms and mutation order influences phenotype","volume":"100","author":"Nangalia","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2026.101385_bb0040","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1038\/leu.2011.77","article-title":"DNMT3A mutations in myeloproliferative neoplasms","volume":"25","author":"Stegelmann","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2026.101385_bb0045","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa1412098","article-title":"Effect of mutation order on myeloproliferative neoplasms","volume":"372","author":"Ortmann","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2026.101385_bb0050","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.hoc.2012.07.006","article-title":"Role of TET2 and ASXL1 mutations in the pathogenesis of myeloproliferative neoplasms","volume":"26","author":"Abdel-Wahab","year":"2012","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.blre.2026.101385_bb0055","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1182\/bloodadvances.2016000216","article-title":"Targeted deep sequencing in polycythemia vera and essential thrombocythemia","volume":"1","author":"Tefferi","year":"2016","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2026.101385_bb0060","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s11899-022-00685-1","article-title":"Molecular Pathogenesis of Myeloproliferative Neoplasms","volume":"17","author":"Rolles","year":"2022","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.blre.2026.101385_bb0065","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.blre.2026.101385_bb0070","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrc2210","article-title":"Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders","volume":"7","author":"Levine","year":"2007","journal-title":"Nat Rev Cancer"},{"issue":"Suppl. 2","key":"10.1016\/j.blre.2026.101385_bb0075","doi-asserted-by":"crossref","first-page":"S307","DOI":"10.1016\/j.clml.2013.07.011","article-title":"Rationale for targeting the PI3K\/Akt\/mTOR pathway in myeloproliferative neoplasms","volume":"13","author":"Bartalucci","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.blre.2026.101385_bb0080","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1158\/1535-7163.MCT-12-0862","article-title":"Dual PI3K\/AKT\/mTOR inhibitor BEZ235 synergistically enhances the activity of JAK2 inhibitor against cultured and primary human myeloproliferative neoplasm cells","volume":"12","author":"Fiskus","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.blre.2026.101385_bb0085","doi-asserted-by":"crossref","first-page":"96710","DOI":"10.18632\/oncotarget.18073","article-title":"Inhibitors of the PI3K\/mTOR pathway prevent STAT5 phosphorylation in JAK2V617F mutated cells through PP2A\/CIP2A axis","volume":"8","author":"Bartalucci","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.blre.2026.101385_bb0090","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1172\/JCI98785","article-title":"Targeting compensatory MEK\/ERK activation increases JAK inhibitor efficacy in myeloproliferative neoplasms","volume":"129","author":"Stivala","year":"2019","journal-title":"J Clin Invest"},{"key":"10.1016\/j.blre.2026.101385_bb0095","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.stem.2021.02.001","article-title":"Reconstructing the Lineage Histories and Differentiation Trajectories of Individual Cancer Cells in Myeloproliferative Neoplasms","volume":"28","author":"Van Egeren","year":"2021","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.blre.2026.101385_bb0100","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1038\/s41591-022-01793-4","article-title":"In utero origin of myelofibrosis presenting in adult monozygotic twins","volume":"28","author":"Sousos","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.blre.2026.101385_bb0105","article-title":"Pathogenesis of Myeloproliferative Neoplasms: Role and Mechanisms of Chronic Inflammation","volume":"2015","author":"Hermouet","year":"2015","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.blre.2026.101385_bb0110","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.leukres.2012.10.020","article-title":"Chronic inflammation as a promotor of mutagenesis in essential thrombocythemia, polycythemia vera and myelofibrosis. A human inflammation model for cancer development?","volume":"37","author":"Hasselbalch","year":"2013","journal-title":"Leuk Res"},{"key":"10.1016\/j.blre.2026.101385_bb0115","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/102476","article-title":"MPNs as Inflammatory Diseases: The Evidence, Consequences, and Perspectives","volume":"2015","author":"Hasselbalch","year":"2015","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.blre.2026.101385_bb0120","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S1470-2045(16)30626-X","article-title":"Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study","volume":"18","author":"Takahashi","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.blre.2026.101385_bb0125","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.stem.2017.07.010","article-title":"Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical Outcomes","volume":"21","author":"Coombs","year":"2017","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.blre.2026.101385_bb0130","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.exphem.2015.08.014","article-title":"Pathogenesis of myeloproliferative neoplasms: More than mutations","volume":"43","author":"Hermouet","year":"2015","journal-title":"Exp Hematol"},{"key":"10.1016\/j.blre.2026.101385_bb0135","doi-asserted-by":"crossref","first-page":"1196817","DOI":"10.3389\/fonc.2023.1196817","article-title":"Mutations, inflammation and phenotype of myeloproliferative neoplasms","volume":"13","author":"Hermouet","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.blre.2026.101385_bb0140","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1182\/blood-2019-129800","article-title":"IL-1\u03b2 Secreted from Mutant Cells Carrying JAK2-V617Ffavors Early Clonal Expansion and Promotes MPN Disease Initiation and Progression","volume":"134","author":"Rai","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101385_bb0145","first-page":"2359","article-title":"Tracking the evolution of therapy-related myeloid neoplasms using chemotherapy signatures","volume":"141","author":"Diamond","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101385_bb0150","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000885","article-title":"Impact of Clonal Architecture on Clinical Course and Prognosis in Patients With Myeloproliferative Neoplasms","volume":"7","author":"Luque Paz","year":"2023","journal-title":"Hemasphere"},{"key":"10.1016\/j.blre.2026.101385_bb0155","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41586-020-2864-x","article-title":"Single-cell mutation analysis of clonal evolution in myeloid malignancies","volume":"587","author":"Miles","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.blre.2026.101385_bb0160","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1182\/bloodadvances.2021005867","article-title":"Single-cell analysis reveals selection of TP53-mutated clones after MDM2 inhibition","volume":"6","author":"Maslah","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2026.101385_bb0165","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1124\/pr.119.018440","article-title":"Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 to Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution","volume":"72","author":"Bharadwaj","year":"2020","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.blre.2026.101385_bb0170","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1038\/s41375-018-0117-x","article-title":"Implications of STAT3 and STAT5 signaling on gene regulation and chromatin remodeling in hematopoietic cancer","volume":"32","author":"Wingelhofer","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2026.101385_bb0175","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.blre.2026.101385_bb0180","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa065202","article-title":"JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis","volume":"356","author":"Scott","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2026.101385_bb0185","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.blre.2026.101385_bb0190","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0030270","article-title":"MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia","volume":"3","author":"Pikman","year":"2006","journal-title":"PLoS Med"},{"key":"10.1016\/j.blre.2026.101385_bb0195","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1182\/blood-2017-06-782037","article-title":"Myeloproliferative neoplasms: from origins to outcomes","volume":"130","author":"Nangalia","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101385_bb0200","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1182\/blood.2022017578","article-title":"Genetic basis and molecular profiling in myeloproliferative neoplasms","volume":"141","author":"Luque Paz","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101385_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2020.100708","article-title":"Genomic heterogeneity in myeloproliferative neoplasms and applications to clinical practice","volume":"42","author":"Lee","year":"2020","journal-title":"Blood Rev"},{"key":"10.1016\/j.blre.2026.101385_bb0210","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1182\/blood.2019000622","article-title":"Mutant calreticulin in myeloproliferative neoplasms","volume":"134","author":"How","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101385_bb0215","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/bs.ircmb.2021.09.003","article-title":"The MPL mutation","volume":"365","author":"Guglielmelli","year":"2021","journal-title":"Int Rev Cell Mol Biol"},{"key":"10.1016\/j.blre.2026.101385_bb0220","doi-asserted-by":"crossref","first-page":"3931","DOI":"10.1182\/blood-2007-08-107748","article-title":"Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice","volume":"111","author":"Tiedt","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101385_bb0225","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1182\/blood-2006-02-002030","article-title":"JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis","volume":"108","author":"Lacout","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101385_bb0230","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1182\/blood-2013-11-539098","article-title":"JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes","volume":"123","author":"Rumi","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101385_bb0235","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.ccr.2010.10.013","article-title":"Distinct clinical phenotypes associated with JAK2V617F reflect differential STAT1 signaling","volume":"18","author":"Chen","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.blre.2026.101385_bb0240","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1182\/blood-2006-04-018259","article-title":"Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia","volume":"108","author":"Scott","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101385_bb0245","first-page":"10","article-title":"Progression of Myeloproliferative Neoplasms (MPN): Diagnostic and Therapeutic Perspectives","author":"Baumeister","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.blre.2026.101385_bb0250","first-page":"12","article-title":"Clonal Hematopoiesis and Mutations of Myeloproliferative Neoplasms","author":"Kj\u00e6r","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.blre.2026.101385_bb0255","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1182\/blood-2016-10-695940","article-title":"Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms","volume":"129","author":"Vainchenker","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101385_bb0260","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1038\/s41375-020-0869-y","article-title":"Prevalence and dynamics of clonal hematopoiesis caused by leukemia-associated mutations in elderly individuals without hematologic disorders","volume":"34","author":"Midic","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2026.101385_bb0265","doi-asserted-by":"crossref","first-page":"1308709","DOI":"10.3389\/fonc.2024.1308709","article-title":"The dark side of stemness - the role of hematopoietic stem cells in development of blood malignancies","volume":"14","author":"Filipek-Gorza\u0142a","year":"2024","journal-title":"Front Oncol"},{"key":"10.1016\/j.blre.2026.101385_bb0270","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1182\/blood-2013-11-537167","article-title":"Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms","volume":"123","author":"Lundberg","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101385_bb0275","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1158\/0008-5472.CAN-09-3783","article-title":"Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias","volume":"70","author":"Abdel-Wahab","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.blre.2026.101385_bb0280","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ccr.2011.06.003","article-title":"TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis","volume":"20","author":"Quivoron","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.blre.2026.101385_bb0285","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1182\/blood-2014-04-567024","article-title":"Distinct effects of concomitant Jak2V617F expression and Tet2 loss in mice promote disease progression in myeloproliferative neoplasms","volume":"125","author":"Chen","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101385_bb0290","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1038\/leu.2011.82","article-title":"DNMT3A mutational analysis in primary myelofibrosis, chronic myelomonocytic leukemia and advanced phases of myeloproliferative neoplasms","volume":"25","author":"Abdel-Wahab","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2026.101385_bb0295","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/ng.1009","article-title":"Dnmt3a is essential for hematopoietic stem cell differentiation","volume":"44","author":"Challen","year":"2011","journal-title":"Nat Genet"},{"key":"10.1016\/j.blre.2026.101385_bb0300","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1002\/gcc.21960","article-title":"Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms","volume":"51","author":"Brecqueville","year":"2012","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.blre.2026.101385_bb0305","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.exphem.2015.11.011","article-title":"Truncation mutants of ASXL1 observed in myeloid malignancies are expressed at detectable protein levels","volume":"44","author":"Inoue","year":"2016","journal-title":"Exp Hematol"},{"key":"10.1016\/j.blre.2026.101385_bb0310","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1182\/bloodadvances.2020003444","article-title":"Genomic analysis of primary and secondary myelofibrosis redefines the prognostic impact of ASXL1 mutations: a FIM study","volume":"5","author":"Paz","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2026.101385_bb0315","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1084\/jem.20151136","article-title":"Loss of Ezh2 synergizes with JAK2-V617F in initiating myeloproliferative neoplasms and promoting myelofibrosis","volume":"213","author":"Shimizu","year":"2016","journal-title":"J Exp Med"},{"key":"10.1016\/j.blre.2026.101385_bb0320","doi-asserted-by":"crossref","first-page":"5227","DOI":"10.1182\/blood-2011-06-363424","article-title":"EZH2 mutational status predicts poor survival in myelofibrosis","volume":"118","author":"Guglielmelli","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101385_bb0325","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/leu.2011.253","article-title":"IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F","volume":"26","author":"Tefferi","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2026.101385_bb0330","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41392-021-00486-7","article-title":"Alternative splicing and cancer: a systematic review","volume":"6","author":"Zhang","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.blre.2026.101385_bb0335","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s10020-024-00839-2","article-title":"Biological relevance of alternative splicing in hematologic malignancies","volume":"30","author":"Szelest","year":"2024","journal-title":"Mol Med"},{"key":"10.1016\/j.blre.2026.101385_bb0340","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/s41588-021-00828-9","article-title":"Minor intron retention drives clonal hematopoietic disorders and diverse cancer predisposition","volume":"53","author":"Inoue","year":"2021","journal-title":"Nat Genet"},{"key":"10.1016\/j.blre.2026.101385_bb0345","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/s41408-023-00947-y","article-title":"SRSF2 mutation reduces polycythemia and impairs hematopoietic progenitor functions in JAK2V617F-driven myeloproliferative neoplasm","volume":"13","author":"Yang","year":"2023","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.blre.2026.101385_bb0350","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1038\/s41375-018-0078-0","article-title":"U2AF1 mutation types in primary myelofibrosis: phenotypic and prognostic distinctions","volume":"32","author":"Tefferi","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2026.101385_bb0355","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1111\/bjh.15010","article-title":"Screening for ASXL1 and SRSF2 mutations is imperative for treatment decision-making in otherwise low or intermediate-1 risk patients with myelofibrosis","volume":"183","author":"Tefferi","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2026.101385_bb0360","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1002\/ajh.24978","article-title":"Driver mutations and prognosis in primary myelofibrosis: Mayo-Careggi MPN alliance study of 1,095 patients","volume":"93","author":"Tefferi","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2026.101385_bb0365","doi-asserted-by":"crossref","first-page":"4480","DOI":"10.1182\/blood-2011-11-390252","article-title":"Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome","volume":"119","author":"Zhang","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101385_bb0370","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/leu.2014.277","article-title":"SRSF2 and U2AF1 mutations in primary myelofibrosis are associated with JAK2 and MPL but not calreticulin mutation and may independently reoccur after allogeneic stem cell transplantation","volume":"29","author":"Bartels","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2026.101385_bb0375","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2","volume":"369","author":"Nangalia","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2026.101385_bb0380","first-page":"3","article-title":"Transcription factors and evolution: An integral part of gene expression (Review)","volume":"2","author":"Mitsis","year":"2020","journal-title":"World Acad Sci J"},{"key":"10.1016\/j.blre.2026.101385_bb0385","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/j.cell.2013.02.014","article-title":"Transcriptional regulation and its misregulation in disease","volume":"152","author":"Lee","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.blre.2026.101385_bb0390","first-page":"23","article-title":"Molecular Pathogenesis of Myeloproliferative Neoplasms: From Molecular Landscape to Therapeutic Implications","author":"Morsia","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.blre.2026.101385_bb0395","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1182\/bloodadvances.2018015875","article-title":"Targeted next-generation sequencing in blast phase myeloproliferative neoplasms","volume":"2","author":"Lasho","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2026.101385_bb0400","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1084\/jem.20120521","article-title":"MPN patients harbor recurrent truncating mutations in transcription factor NF-E2","volume":"210","author":"Jutzi","year":"2013","journal-title":"J Exp Med"},{"key":"10.1016\/j.blre.2026.101385_bb0405","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nrc.2015.2","article-title":"DNA damage and the balance between survival and death in cancer biology","volume":"16","author":"Roos","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.blre.2026.101385_bb0410","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nri1804","article-title":"DNA damage: a trigger of innate immunity but a requirement for adaptive immune homeostasis","volume":"6","author":"Xu","year":"2006","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.blre.2026.101385_bb0415","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1080\/10428194.2020.1817441","article-title":"The expression of MDM2, MDM4, p53 and p21 in myeloid neoplasms and the effect of MDM2\/MDM4 dual inhibitor","volume":"62","author":"Eskandari","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2026.101385_bb0420","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1056\/NEJMoa1716614","article-title":"Classification and Personalized Prognosis in Myeloproliferative Neoplasms","volume":"379","author":"Grinfeld","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2026.101385_bb0425","doi-asserted-by":"crossref","first-page":"4887","DOI":"10.1182\/bloodadvances.2020002271","article-title":"Leukemic evolution of polycythemia vera and essential thrombocythemia: genomic profiles predict time to transformation","volume":"4","author":"Paz","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2026.101385_bb0430","doi-asserted-by":"crossref","first-page":"E5401","DOI":"10.1073\/pnas.1407792111","article-title":"Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms","volume":"111","author":"Rampal","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.blre.2026.101385_bb0435","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1111\/bjh.14762","article-title":"Impact of genotype on leukaemic transformation in polycythaemia vera and essential thrombocythaemia","volume":"178","author":"Alvarez-Larr\u00e1n","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2026.101385_bb0440","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1056\/NEJMc1012718","article-title":"p53 lesions in leukemic transformation","volume":"364","author":"Harutyunyan","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2026.101385_bb0445","series-title":"PPM1D Mutations Drive Clonal Hematopoiesis in Response to Cytotoxic Chemotherapy","volume":"23","year":"2018"},{"key":"10.1016\/j.blre.2026.101385_bb0450","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1182\/blood-2018-05-850339","article-title":"PPM1D-truncating mutations confer resistance to chemotherapy and sensitivity to PPM1D inhibition in hematopoietic cells","volume":"132","author":"Kahn","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101385_bb0455","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1056\/NEJMoa1611604","article-title":"Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation","volume":"376","author":"Lindsley","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2026.101385_bb0460","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.2023020331","article-title":"PPM1D modulates hematopoietic cell fitness and response to DNA damage and is a therapeutic target in myeloid malignancy","volume":"142","author":"Miller","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101385_bb0465","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1038\/s41588-020-00710-0","article-title":"Cancer therapy shapes the fitness landscape of clonal hematopoiesis","volume":"52","author":"Bolton","year":"2020","journal-title":"Nat Genet"},{"key":"10.1016\/j.blre.2026.101385_bb0470","first-page":"4","article-title":"Fitness Landscape of Clonal Hematopoiesis Under Selective Pressure of Immune Checkpoint Blockade. JCO Precis","author":"Miller","year":"2020","journal-title":"Oncol"},{"key":"10.1016\/j.blre.2026.101385_bb0475","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1200\/JCO.2016.71.6712","article-title":"Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma","volume":"35","author":"Gibson","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2026.101385_bb0480","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1182\/blood-2015-07-661983","article-title":"Presence of atypical thrombopoietin receptor (MPL) mutations in triple-negative essential thrombocythemia patients","volume":"127","author":"Cabagnols","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101385_bb0485","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1182\/blood-2015-07-661835","article-title":"Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms","volume":"127","author":"Feenstra","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101385_bb0490","doi-asserted-by":"crossref","first-page":"E264","DOI":"10.1002\/ajh.25580","article-title":"Diagnostic and prognostic contribution of targeted NGS in patients with triple-negative myeloproliferative neoplasms","volume":"94","author":"Acha","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2026.101385_bb0495","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.3324\/haematol.2022.280917","article-title":"Histological and genetic characterization and follow-up of 130 patients with chronic triple-negative thrombocytosis","volume":"107","author":"Lemoine","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2026.101385_bb0500","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1182\/blood-2016-02-698951","article-title":"Cooperation of germ line JAK2 mutations E846D and R1063H in hereditary erythrocytosis with megakaryocytic atypia","volume":"128","author":"Kapralova","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101385_bb0505","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3324\/haematol.2009.007542","article-title":"Hereditary thrombocytosis caused by MPLSer505Asn is associated with a high thrombotic risk, splenomegaly and progression to bone marrow fibrosis","volume":"95","author":"Teofili","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2026.101385_bb0510","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1056\/NEJMc1200349","article-title":"Germline JAK2 mutation in a family with hereditary thrombocytosis","volume":"366","author":"Mead","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2026.101385_bb0515","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1111\/bjh.15954","article-title":"Next generation sequencing redefines a triple negative essential thrombocythaemia as double-positive with rare mutations on JAK2 V617 and MPL W515 hotspots","volume":"186","author":"Beucher","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2026.101385_bb0520","doi-asserted-by":"crossref","first-page":"5284","DOI":"10.1038\/s41467-022-32986-7","article-title":"Germline-somatic JAK2 interactions are associated with clonal expansion in myelofibrosis","volume":"13","author":"Brown","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.blre.2026.101385_bb0525","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/s41586-019-1618-0","article-title":"Coordinated alterations in RNA splicing and epigenetic regulation drive leukaemogenesis","volume":"574","author":"Yoshimi","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.blre.2026.101385_bb0530","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1038\/s41375-018-0077-1","article-title":"Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet","volume":"32","author":"Barbui","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2026.101385_bb0535","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/bjh.18834","article-title":"Molecular-defined clonal evolution in patients with classical myeloproliferative neoplasms","volume":"202","author":"Hinze","year":"2023","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2026.101385_bb0540","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1038\/leu.2014.3","article-title":"CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2026.101385_bb0545","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1038\/leu.2013.119","article-title":"Mutations and prognosis in primary myelofibrosis","volume":"27","author":"Vannucchi","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2026.101385_bb0550","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1200\/JCO.2018.78.9867","article-title":"MIPSS70+ Version 2.0: Mutation and Karyotype-Enhanced International Prognostic Scoring System for Primary Myelofibrosis","volume":"36","author":"Tefferi","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2026.101385_bb0555","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1038\/s41375-018-0107-z","article-title":"GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis","volume":"32","author":"Tefferi","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2026.101385_bb0560","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/s41375-019-0603-9","article-title":"Prognostic impact of RAS-pathway mutations in patients with myelofibrosis","volume":"34","author":"Santos","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2026.101385_bb0565","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1038\/leu.2014.76","article-title":"The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients","volume":"28","author":"Guglielmelli","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2026.101385_bb0570","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1200\/JCO.2017.76.4886","article-title":"MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis","volume":"36","author":"Guglielmelli","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2026.101385_bb0575","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1182\/bloodadvances.2021006350","article-title":"ASXL1 mutations are prognostically significant in PMF, but not MF following essential thrombocythemia or polycythemia vera","volume":"6","author":"Guglielmelli","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2026.101385_bb0580","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/bjh.14269","article-title":"Application of an NGS-based 28-gene panel in myeloproliferative neoplasms reveals distinct mutation patterns in essential thrombocythaemia, primary myelofibrosis and polycythaemia vera","volume":"175","author":"Delic","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2026.101385_bb0585","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1038\/s41375-018-0018-z","article-title":"Revised cytogenetic risk stratification in primary myelofibrosis: analysis based on 1002 informative patients","volume":"32","author":"Tefferi","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2026.101385_bb0590","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1182\/blood-2011-01-331678","article-title":"Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression","volume":"118","author":"Klampfl","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101385_bb0595","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/gcc.22789","article-title":"Targeted molecular characterization shows differences between primary and secondary myelofibrosis","volume":"59","author":"Courtier","year":"2020","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.blre.2026.101385_bb0600","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41586-022-05448-9","article-title":"Common and rare variant associations with clonal haematopoiesis phenotypes","volume":"612","author":"Kessler","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.blre.2026.101385_bb0605","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1056\/NEJMoa1409405","article-title":"Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence","volume":"371","author":"Genovese","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2026.101385_bb0610","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2026.101385_bb0615","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/s41586-018-0497-0","article-title":"Population dynamics of normal human blood inferred from somatic mutations","volume":"561","author":"Lee-Six","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.blre.2026.101385_bb0620","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1016\/j.celrep.2018.11.014","article-title":"Somatic Mutations Reveal Lineage Relationships and Age-Related Mutagenesis in Human Hematopoiesis","volume":"25","author":"Osorio","year":"2018","journal-title":"Cell Rep"},{"key":"10.1016\/j.blre.2026.101385_bb0625","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.cell.2012.06.023","article-title":"The origin and evolution of mutations in acute myeloid leukemia","volume":"150","author":"Welch","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.blre.2026.101385_bb0630","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1182\/blood.2019001113","article-title":"Prevalence and phenotypes of JAK2 V617F and calreticulin mutations in a Danish general population","volume":"134","author":"Cordua","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101385_bb0635","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1701719","article-title":"Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease","volume":"377","author":"Jaiswal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2026.101385_bb0640","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/s41586-018-0317-6","article-title":"Prediction of acute myeloid leukaemia risk in healthy individuals","volume":"559","author":"Abelson","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.blre.2026.101385_bb0645","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1038\/s41591-018-0081-z","article-title":"Somatic mutations precede acute myeloid leukemia years before diagnosis","volume":"24","author":"Desai","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.blre.2026.101385_bb0650","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1161\/CIRCULATIONAHA.119.044362","article-title":"Genetic Interleukin 6 Signaling Deficiency Attenuates Cardiovascular Risk in Clonal Hematopoiesis","volume":"141","author":"Bick","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.blre.2026.101385_bb0655","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1001\/jamacardio.2018.3965","article-title":"Association of Mutations Contributing to Clonal Hematopoiesis With Prognosis in Chronic Ischemic Heart Failure","volume":"4","author":"Dorsheimer","year":"2019","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.blre.2026.101385_bb0660","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.3324\/haematol.2018.215269","article-title":"Clonal hematopoiesis and risk of acute myeloid leukemia","volume":"104","author":"Young","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2026.101385_bb0665","doi-asserted-by":"crossref","unstructured":"Bhattacharya R, Zekavat SM, Haessler J, Fornage M, Raffield L, Uddin MM, et al. Clonal Hematopoiesis Is Associated With Higher Risk of Stroke. Stroke 2022;53:788\u201397. Doi: https:\/\/doi.org\/10.1161\/STROKEAHA.121.037388.","DOI":"10.1161\/STROKEAHA.121.037388"},{"key":"10.1016\/j.blre.2026.101385_bb0670","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1182\/blood.2022017661","article-title":"Associations of clonal hematopoiesis with recurrent vascular events and death in patients with incident ischemic stroke","volume":"141","author":"Arends","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101385_bb0675","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1002\/ajh.26915","article-title":"Clonal hematopoiesis of indeterminate potential and clonal cytopenias of undetermined significance: 2023 update on clinical associations and management recommendations","volume":"98","author":"Mangaonkar","year":"2023","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2026.101385_bb0680","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.yjmcc.2021.07.004","article-title":"Clonal hematopoiesis of indeterminate potential (CHIP): Linking somatic mutations, hematopoiesis, chronic inflammation and cardiovascular disease","volume":"161","author":"Marnell","year":"2021","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.blre.2026.101385_bb0685","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1182\/bloodadvances.2017007047","article-title":"JAK2 V617F hematopoietic clones are present several years prior to MPN diagnosis and follow different expansion kinetics","volume":"1","author":"McKerrell","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2026.101385_bb0690","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ajhg.2017.05.013","article-title":"Ultra-sensitive Sequencing Identifies High Prevalence of Clonal Hematopoiesis-Associated Mutations throughout Adult Life","volume":"101","author":"Acuna-Hidalgo","year":"2017","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.blre.2026.101385_bb0695","doi-asserted-by":"crossref","first-page":"2848","DOI":"10.1182\/blood-2017-05-784942","article-title":"Ruxolitinib-induced defects in DNA repair cause sensitivity to PARP inhibitors in myeloproliferative neoplasms","volume":"130","author":"Nieborowska-Skorska","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101385_bb0700","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1038\/leu.2013.102","article-title":"A role for reactive oxygen species in JAK2V617F myeloproliferative neoplasm progression","volume":"27","author":"Marty","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2026.101385_bb0705","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/s41586-021-04312-6","article-title":"Life histories of myeloproliferative neoplasms inferred from phylogenies","volume":"602","author":"Williams","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.blre.2026.101385_bb0710","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/s41586-022-04785-z","article-title":"The longitudinal dynamics and natural history of clonal haematopoiesis","volume":"606","author":"Fabre","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.blre.2026.101385_bb0715","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/s41586-022-04786-y","article-title":"Clonal dynamics of haematopoiesis across the human lifespan","volume":"606","author":"Mitchell","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.blre.2026.101385_bb0720","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/s41586-020-2819-2","article-title":"Inherited causes of clonal haematopoiesis in 97,691 whole genomes","volume":"586","author":"Bick","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.blre.2026.101385_bb0725","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2120374119","article-title":"Inferring the initiation and development of myeloproliferative neoplasms","volume":"119","author":"Hermange","year":"2022","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.blre.2026.101385_bb0730","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1182\/blood-2013-04-498956","article-title":"JAK2V617F expression in mice amplifies early hematopoietic cells and gives them a competitive advantage that is hampered by IFN\u03b1","volume":"122","author":"Hasan","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101385_bb0735","doi-asserted-by":"crossref","first-page":"4886","DOI":"10.1038\/s41467-020-18691-3","article-title":"Calreticulin del52 and ins5 knock-in mice recapitulate different myeloproliferative phenotypes observed in patients with MPN","volume":"11","author":"Benlabiod","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.blre.2026.101385_bb0740","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1084\/jem.20131371","article-title":"Myeloproliferative neoplasms can be initiated from a single hematopoietic stem cell expressing JAK2-V617F","volume":"211","author":"Lundberg","year":"2014","journal-title":"J Exp Med"},{"key":"10.1016\/j.blre.2026.101385_bb0745","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1182\/blood-2010-12-327593","article-title":"Effects of the JAK2 mutation on the hematopoietic stem and progenitor compartment in human myeloproliferative neoplasms","volume":"118","author":"Anand","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101385_bb0750","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1182\/blood-2006-10-054940","article-title":"The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera","volume":"110","author":"Dupont","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101385_bb0755","doi-asserted-by":"crossref","first-page":"5323","DOI":"10.1038\/s41388-020-1368-3","article-title":"Different impact of calreticulin mutations on human hematopoiesis in myeloproliferative neoplasms","volume":"39","author":"El-Khoury","year":"2020","journal-title":"Oncogene"},{"key":"10.1016\/j.blre.2026.101385_bb0760","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.celrep.2015.02.005","article-title":"Leukemia-associated somatic mutations drive distinct patterns of age-related clonal hemopoiesis","volume":"10","author":"McKerrell","year":"2015","journal-title":"Cell Rep"},{"key":"10.1016\/j.blre.2026.101385_bb0765","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s00277-017-2937-6","article-title":"Clinicopathological differences exist between CALR- and JAK2-mutated myeloproliferative neoplasms despite a similar molecular landscape: data from targeted next-generation sequencing in the diagnostic laboratory","volume":"96","author":"Agarwal","year":"2017","journal-title":"Ann Hematol"},{"key":"10.1016\/j.blre.2026.101385_bb0770","doi-asserted-by":"crossref","unstructured":"Plo I, Nakatake M, Malivert L, Villartay J-P de, Giraudier S, Villeval J-L, et al. JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders. Blood 2008;112:1402\u201312. Doi: https:\/\/doi.org\/10.1182\/blood-2008-01-134114.","DOI":"10.1182\/blood-2008-01-134114"},{"key":"10.1016\/j.blre.2026.101385_bb0775","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41408-018-0166-4","article-title":"High frequencies of circulating memory T cells specific for calreticulin exon 9 mutations in healthy individuals","volume":"9","author":"Holmstr\u00f6m","year":"2019","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.blre.2026.101385_bb0780","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1182\/blood.2019000519","article-title":"Mutational landscape of the transcriptome offers putative targets for immunotherapy of myeloproliferative neoplasms","volume":"134","author":"Schischlik","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101385_bb0785","first-page":"1269","article-title":"Emerging technologies of single-cell multi-omics","volume":"110","author":"Kim","year":"2025","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2026.101385_bb0790","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1056\/NEJM197610212951702","article-title":"Polycythemia vera: stem-cell and probable clonal origin of the disease","volume":"295","author":"Adamson","year":"1976","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2026.101385_bb0795","doi-asserted-by":"crossref","first-page":"6848","DOI":"10.1073\/pnas.88.15.6848","article-title":"Clonality in myeloproliferative disorders: analysis by means of the polymerase chain reaction","volume":"88","author":"Gilliland","year":"1991","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.blre.2026.101385_bb0800","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/j.1365-2141.1966.tb00134.x","article-title":"The chromosomes in polycythaemia vera","volume":"12","author":"Kay","year":"1966","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2026.101385_bb0805","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/nmeth.1315","article-title":"mRNA-Seq whole-transcriptome analysis of a single cell","volume":"6","author":"Tang","year":"2009","journal-title":"Nat Methods"},{"key":"10.1016\/j.blre.2026.101385_bb0810","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1101\/gr.110882.110","article-title":"Characterization of the single-cell transcriptional landscape by highly multiplex RNA-seq","volume":"21","author":"Islam","year":"2011","journal-title":"Genome Res"},{"key":"10.1016\/j.blre.2026.101385_bb0815","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.trecan.2023.05.004","article-title":"Clonal evolution and hierarchy in myeloid malignancies","volume":"9","author":"Takahashi","year":"2023","journal-title":"Trends Cancer"},{"key":"10.1016\/j.blre.2026.101385_bb0820","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.cell.2012.02.028","article-title":"Single-cell exome sequencing and monoclonal evolution of a JAK2-negative myeloproliferative neoplasm","volume":"148","author":"Hou","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.blre.2026.101385_bb0825","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1101\/gr.232272.117","article-title":"High-throughput single-cell DNA sequencing of acute myeloid leukemia tumors with droplet microfluidics","volume":"28","author":"Pellegrino","year":"2018","journal-title":"Genome Res"},{"key":"10.1016\/j.blre.2026.101385_bb0830","doi-asserted-by":"crossref","first-page":"313","DOI":"10.3324\/haematol.2020.260448","article-title":"Clonal independence of JAK2 and CALR or MPL mutations in comutated myeloproliferative neoplasms demonstrated by single cell DNA sequencing","volume":"106","author":"Thompson","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2026.101385_bb0835","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1038\/s41467-021-21810-3","article-title":"Joint profiling of DNA and proteins in single cells to dissect genotype-phenotype associations in leukemia","volume":"12","author":"Demaree","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.blre.2026.101385_bb0840","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/s41586-019-1367-0","article-title":"Somatic mutations and cell identity linked by Genotyping of Transcriptomes","volume":"571","author":"Nam","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.blre.2026.101385_bb0845","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/j.cell.2019.01.022","article-title":"Lineage Tracing in Humans Enabled by Mitochondrial Mutations and Single-Cell Genomics","volume":"176","author":"Ludwig","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.blre.2026.101385_bb0850","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1038\/s41587-022-01210-8","article-title":"Mitochondrial variant enrichment from high-throughput single-cell RNA sequencing resolves clonal populations","volume":"40","author":"Miller","year":"2022","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.blre.2026.101385_bb0855","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1038\/nmeth.2688","article-title":"Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position","volume":"10","author":"Buenrostro","year":"2013","journal-title":"Nat Methods"},{"key":"10.1016\/j.blre.2026.101385_bb0860","doi-asserted-by":"crossref","first-page":"5183","DOI":"10.1016\/j.cell.2023.09.019","article-title":"A mouse model with high clonal barcode diversity for joint lineage, transcriptomic, and epigenomic profiling in single cells","volume":"186","author":"Li","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.blre.2026.101385_bb0865","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.tig.2010.05.003","article-title":"Evolution of the mutation rate","volume":"26","author":"Lynch","year":"2010","journal-title":"Trends Genet"},{"key":"10.1016\/j.blre.2026.101385_bb0870","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1038\/s41586-025-09041-8","article-title":"Clonal tracing with somatic epimutations reveals dynamics of blood ageing","volume":"643","author":"Scherer","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.blre.2026.101385_bb0875","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/s41592-024-02567-1","article-title":"High-resolution, noninvasive single-cell lineage tracing in mice and humans based on DNA methylation epimutations","volume":"22","author":"Chen","year":"2025","journal-title":"Nat Methods"},{"key":"10.1016\/j.blre.2026.101385_bb0880","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/j.molcel.2019.01.009","article-title":"Unravelling Intratumoral Heterogeneity through High-Sensitivity Single-Cell Mutational Analysis and Parallel RNA Sequencing","volume":"73","author":"Rodriguez-Meira","year":"2019","journal-title":"Mol Cell"},{"key":"10.1016\/j.blre.2026.101385_bb0885","doi-asserted-by":"crossref","first-page":"3613","DOI":"10.1182\/blood-2010-06-289207","article-title":"Impact of gene dosage, loss of wild-type allele, and FLT3 ligand on Flt3-ITD-induced myeloproliferation","volume":"118","author":"Kharazi","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101385_bb0890","article-title":"Unifying genomics and transcriptomics in single cells with ResolveOME amplification chemistry to illuminate oncogenic and drug resistance mechanisms","author":"Zawistowski","year":"2022","journal-title":"bioRxiv"},{"key":"10.1016\/j.blre.2026.101385_bb0895","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.cell.2020.06.032","article-title":"Coupled scRNA-Seq and Intracellular Protein Activity Reveal an Immunosuppressive Role of TREM2 in Cancer","volume":"182","author":"Katzenelenbogen","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.blre.2026.101385_bb0900","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/s42003-021-02142-w","article-title":"A combined approach for single-cell mRNA and intracellular protein expression analysis","volume":"4","author":"Reimeg\u00e5rd","year":"2021","journal-title":"Commun Biol"},{"key":"10.1016\/j.blre.2026.101385_bb0905","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1038\/s41586-024-07388-y","article-title":"Mapping genotypes to chromatin accessibility profiles in single cells","volume":"629","author":"Izzo","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.blre.2026.101385_bb0910","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.stem.2023.07.012","article-title":"Single-cell multi-omics defines the cell-type-specific impact of splicing aberrations in human hematopoietic clonal outgrowths","volume":"30","author":"Cort\u00e9s-L\u00f3pez","year":"2023","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.blre.2026.101385_bb0915","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/s41586-019-1198-z","article-title":"Epigenetic evolution and lineage histories of chronic lymphocytic leukaemia","volume":"569","author":"Gaiti","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.blre.2026.101385_bb0920","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/s41594-018-0046-4","article-title":"Global delay in nascent strand DNA methylation","volume":"25","author":"Charlton","year":"2018","journal-title":"Nat Struct Mol Biol"},{"key":"10.1016\/j.blre.2026.101385_bb0925","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1038\/cr.2016.23","article-title":"Single-cell triple omics sequencing reveals genetic, epigenetic, and transcriptomic heterogeneity in hepatocellular carcinomas","volume":"26","author":"Hou","year":"2016","journal-title":"Cell Res"},{"key":"10.1016\/j.blre.2026.101385_bb0930","series-title":"Moore L","author":"Williams","year":"2020"},{"key":"10.1016\/j.blre.2026.101385_bb0935","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.stem.2021.02.018","article-title":"Myeloproliferative Neoplasms: The Long Wait for JAK2-Mutant Clone Expansion","volume":"28","author":"Luque Paz","year":"2021","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.blre.2026.101385_bb0940","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0183620","article-title":"Mathematical modelling as a proof of concept for MPNs as a human inflammation model for cancer development","volume":"12","author":"Andersen","year":"2017","journal-title":"PloS One"},{"key":"10.1016\/j.blre.2026.101385_bb0945","doi-asserted-by":"crossref","first-page":"187","DOI":"10.3389\/fonc.2016.00187","article-title":"DNMT3A and TET2 in the Pre-Leukemic Phase of Hematopoietic Disorders","volume":"6","author":"Sato","year":"2016","journal-title":"Front Oncol"},{"key":"10.1016\/j.blre.2026.101385_bb0950","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1007\/s12185-013-1407-8","article-title":"Role of DNMT3A, TET2, and IDH1\/2 mutations in pre-leukemic stem cells in acute myeloid leukemia","volume":"98","author":"Chan","year":"2013","journal-title":"Int J Hematol"},{"key":"10.1016\/j.blre.2026.101385_bb0955","first-page":"7","article-title":"DNMT3A in Leukemia","author":"Brunetti","year":"2017","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.blre.2026.101385_bb0960","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.bbcan.2017.01.003","article-title":"Tumor evolution: Linear, branching, neutral or punctuated?","volume":"1867","author":"Davis","year":"2017","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"10.1016\/j.blre.2026.101385_bb0965","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/leu.2015.207","article-title":"Next-generation deep-sequencing detects multiple clones of CALR mutations in patients with BCR-ABL1 negative MPN","volume":"30","author":"Jeromin","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2026.101385_bb0970","article-title":"A Review of Clonal Relationships in Myeloproliferative Neoplasms with Co-mutations of JAK2, CALR or MPL and BCR::ABL1","author":"Noorafrooz","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.blre.2026.101385_bb0975","doi-asserted-by":"crossref","unstructured":"Manz K, Schnoeder T, Palandri F, Branzanti F, Pahl H, Griesshammer M, et al. MPN with multiple driver clones show distinct patterns of therapy response and progression - \u201cMPN double driver.\u201d Blood 2025;146:1021\u20131021. Doi: https:\/\/doi.org\/10.1182\/blood-2025-1021.","DOI":"10.1182\/blood-2025-1021"},{"key":"10.1016\/j.blre.2026.101385_bb0980","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.ccr.2012.06.032","article-title":"ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression","volume":"22","author":"Abdel-Wahab","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.blre.2026.101385_bb0985","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1084\/jem.20171151","article-title":"Expression of mutant Asxl1 perturbs hematopoiesis and promotes susceptibility to leukemic transformation","volume":"215","author":"Nagase","year":"2018","journal-title":"J Exp Med"},{"key":"10.1016\/j.blre.2026.101385_bb0990","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1172\/JCI94516","article-title":"JAK2\/IDH-mutant-driven myeloproliferative neoplasm is sensitive to combined targeted inhibition","volume":"128","author":"McKenney","year":"2018","journal-title":"J Clin Invest"},{"key":"10.1016\/j.blre.2026.101385_bb0995","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s00277-017-3193-5","article-title":"Non-driver mutations in patients with JAK2V617F-mutated polycythemia vera or essential thrombocythemia with long-term molecular follow-up","volume":"97","author":"Sen\u00edn","year":"2018","journal-title":"Ann Hematol"},{"key":"10.1016\/j.blre.2026.101385_bb1000","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/bs.ircmb.2021.02.008","article-title":"Mutational landscape of blast phase myeloproliferative neoplasms (MPN-BP) and antecedent MPN","volume":"366","author":"Pasca","year":"2022","journal-title":"Int Rev Cell Mol Biol"},{"key":"10.1016\/j.blre.2026.101385_bb1005","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1158\/2159-8290.CD-22-0952","article-title":"Jak2V617F Reversible Activation Shows Its Essential Requirement in Myeloproliferative Neoplasms","volume":"14","author":"Dunbar","year":"2024","journal-title":"Cancer Discov"},{"key":"10.1016\/j.blre.2026.101385_bb1010","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1182\/blood.2023020270","article-title":"Loss of Dnmt3a increases self-renewal and resistance to pegIFN-\u03b1 in JAK2-V617F\u2013positive myeloproliferative neoplasms","volume":"143","author":"Usart","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101385_bb1015","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2020.100711","article-title":"Role of inflammation in the biology of myeloproliferative neoplasms","volume":"42","author":"Koschmieder","year":"2020","journal-title":"Blood Rev"},{"key":"10.1016\/j.blre.2026.101385_bb1020","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.immuni.2008.03.002","article-title":"Cytokine signaling modules in inflammatory responses","volume":"28","author":"O\u2019Shea","year":"2008","journal-title":"Immunity"},{"key":"10.1016\/j.blre.2026.101385_bb1025","volume":"2","author":"Jang","year":"2013","journal-title":"JAK-STAT pathway and myogenic differentiation JAKSTAT"},{"key":"10.1016\/j.blre.2026.101385_bb1030","first-page":"12","article-title":"Anti-Glucosylsphingosine Autoimmunity, JAK2V617F-Dependent Interleukin-1\u03b2 and JAK2V617F-Independent Cytokines in Myeloproliferative Neoplasms","author":"Allain-Maillet","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.blre.2026.101385_bb1035","first-page":"402","article-title":"The JAK\/STAT signaling pathway: from bench to clinic. Signal Transduction and Targeted","volume":"6","author":"Hu","year":"2021","journal-title":"Therapy"},{"key":"10.1016\/j.blre.2026.101385_bb1040","article-title":"Effects of clinically relevant MPL mutations in the transmembrane domain revealed at the atomic level through computational modeling","volume":"6","author":"Lee","year":"2011","journal-title":"PloS One"},{"key":"10.1016\/j.blre.2026.101385_bb1045","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.thromres.2019.05.008","article-title":"Modulation of megakaryopoiesis and platelet production during inflammation","volume":"179","author":"Couldwell","year":"2019","journal-title":"Thromb Res"},{"key":"10.1016\/j.blre.2026.101385_bb1050","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.906698","article-title":"Megakaryocytes Are Regulators of the Tumor Microenvironment and Malignant Hematopoietic Progenitor Cells in Myelofibrosis","volume":"12","author":"Varricchio","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.blre.2026.101385_bb1055","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2020.100280","article-title":"Loss-of-function polymorphism in IL6R reduces risk of JAK2V617F somatic mutation and myeloproliferative neoplasm: A Mendelian randomization study","volume":"21","author":"Pedersen","year":"2020","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.blre.2026.101385_bb1060","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1182\/blood-2006-03-007146","article-title":"Evidence that the JAK2 G1849T (V617F) mutation occurs in a lymphomyeloid progenitor in polycythemia vera and idiopathic myelofibrosis","volume":"109","author":"Delhommeau","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101385_bb1065","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.blre.2017.05.001","article-title":"Interleukin-1\u03b2 as emerging therapeutic target in hematological malignancies and potentially in their complications","volume":"31","author":"Arranz","year":"2017","journal-title":"Blood Rev"},{"key":"10.1016\/j.blre.2026.101385_bb1070","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1182\/bloodadvances.2023011338","article-title":"IL-1\u03b2 promotes MPN disease initiation by favoring early clonal expansion of JAK2-mutant hematopoietic stem cells","volume":"8","author":"Rai","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2026.101385_bb1075","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1161\/CIRCRESAHA.118.313225","article-title":"CRISPR-Mediated Gene Editing to Assess the Roles of Tet2 and Dnmt3a in Clonal Hematopoiesis and Cardiovascular Disease","volume":"123","author":"Sano","year":"2018","journal-title":"Circ Res"},{"key":"10.1016\/j.blre.2026.101385_bb1080","doi-asserted-by":"crossref","first-page":"1134661","DOI":"10.3389\/fimmu.2023.1134661","article-title":"NF-\u03baB in monocytes and macrophages - an inflammatory master regulator in multitalented immune cells","volume":"14","author":"Mussbacher","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.blre.2026.101385_bb1085","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.smim.2013.10.008","article-title":"Treating inflammation by blocking interleukin-1 in humans","volume":"25","author":"Dinarello","year":"2013","journal-title":"Semin Immunol"},{"key":"10.1016\/j.blre.2026.101385_bb1090","doi-asserted-by":"crossref","first-page":"5346","DOI":"10.1038\/s41467-022-32927-4","article-title":"Inhibition of interleukin-1\u03b2 reduces myelofibrosis and osteosclerosis in mice with JAK2-V617F driven myeloproliferative neoplasm","volume":"13","author":"Rai","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.blre.2026.101385_bb1095","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1158\/2159-8290.CD-22-0086","article-title":"Distinct Tumor Necrosis Factor Alpha Receptors Dictate Stem Cell Fitness versus Lineage Output in Dnmt3a-Mutant Clonal Hematopoiesis","volume":"12","author":"SanMiguel","year":"2022","journal-title":"Cancer Discov"},{"key":"10.1016\/j.blre.2026.101385_bb1100","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1182\/blood.2022016835","article-title":"Aging drives Tet2+\/- clonal hematopoiesis via IL-1 signaling","volume":"141","author":"Caiado","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101385_bb1105","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1038\/s41588-023-01480-1","article-title":"Single-cell multi-omics identifies chronic inflammation as a driver of TP53-mutant leukemic evolution","volume":"55","author":"Rodriguez-Meira","year":"2023","journal-title":"Nat Genet"},{"key":"10.1016\/j.blre.2026.101385_bb1110","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/s41590-020-0663-z","article-title":"Adaptive response to inflammation contributes to sustained myelopoiesis and confers a competitive advantage in myelodysplastic syndrome HSCs","volume":"21","author":"Muto","year":"2020","journal-title":"Nat Immunol"},{"key":"10.1016\/j.blre.2026.101385_bb1115","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1016\/j.stem.2021.03.002","article-title":"Chronic infection drives Dnmt3a-loss-of-function clonal hematopoiesis via IFN\u03b3 signaling","volume":"28","author":"Hormaechea-Agulla","year":"2021","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.blre.2026.101385_bb1120","first-page":"9","article-title":"MPN: The Molecular Drivers of Disease Initiation","author":"Grabek","year":"2020","journal-title":"Progression and Transformation and their Effect on Treatment Cells"},{"key":"10.1016\/j.blre.2026.101385_bb1125","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1038\/leu.2013.163","article-title":"Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study","volume":"27","author":"Tefferi","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2026.101385_bb1130","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1038\/s41375-023-01878-0","article-title":"SRSF2-P95H decreases JAK\/STAT signaling in hematopoietic cells and delays myelofibrosis development in mice","volume":"37","author":"Willekens","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2026.101385_bb1135","doi-asserted-by":"crossref","first-page":"5796","DOI":"10.1002\/cam4.1815","article-title":"Smoking is associated with increased risk of myeloproliferative neoplasms: A general population-based cohort study","volume":"7","author":"Pedersen","year":"2018","journal-title":"Cancer Med"},{"key":"10.1016\/j.blre.2026.101385_bb1140","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1182\/blood-2011-11-394775","article-title":"Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer?","volume":"119","author":"Hasselbalch","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101385_bb1145","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1200\/JCO.2011.34.8540","article-title":"Chronic immune stimulation might act as a trigger for the development of acute myeloid leukemia or myelodysplastic syndromes","volume":"29","author":"Kristinsson","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2026.101385_bb1150","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.3324\/haematol.2009.020412","article-title":"Autoimmunity and the risk of myeloproliferative neoplasms","volume":"95","author":"Kristinsson","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2026.101385_bb1155","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/sj.bjc.6604935","article-title":"Risks of myeloid malignancies in patients with autoimmune conditions","volume":"100","author":"Anderson","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1016\/j.blre.2026.101385_bb1160","first-page":"8","article-title":"Roles of JAK2 in Aging, Inflammation, Hematopoiesis and Malignant Transformation","author":"Perner","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.blre.2026.101385_bb1165","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1038\/s41375-020-0896-8","article-title":"Clonal myelopoiesis in the UK Biobank cohort: ASXL1 mutations are strongly associated with smoking","volume":"34","author":"Dawoud","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2026.101385_bb1170","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000327","article-title":"Modifiable Lifestyle and Medical Risk Factors Associated With Myeloproliferative Neoplasms","volume":"4","author":"Duncombe","year":"2020","journal-title":"Hemasphere"},{"key":"10.1016\/j.blre.2026.101385_bb1175","doi-asserted-by":"crossref","unstructured":"Ramanathan G, Chen JH, Mehrotra N, Trieu T, Huang A, Mas E, et al. Cigarette smoke stimulates clonal expansion of Jak2(V617F) and Tet2(-\/-) cells. Front Oncol 2023;13:1210528. Doi: https:\/\/doi.org\/10.3389\/fonc.2023.1210528.","DOI":"10.3389\/fonc.2023.1210528"},{"key":"10.1016\/j.blre.2026.101385_bb1180","first-page":"133","article-title":"Obesity-induced inflammation exacerbates clonal hematopoiesis","author":"Pasupuleti","year":"2023","journal-title":"J Clin Invest"},{"key":"10.1016\/j.blre.2026.101385_bb1185","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.canep.2013.10.009","article-title":"Community-acquired infections and their association with myeloid malignancies","volume":"38","author":"Titmarsh","year":"2014","journal-title":"Cancer Epidemiol"},{"key":"10.1016\/j.blre.2026.101385_bb1190","doi-asserted-by":"crossref","first-page":"5347","DOI":"10.1038\/s41467-022-32928-3","article-title":"Interleukin-1 contributes to clonal expansion and progression of bone marrow fibrosis in JAK2V617F-induced myeloproliferative neoplasm","volume":"13","author":"Rahman","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.blre.2026.101385_bb1195","doi-asserted-by":"crossref","first-page":"6392","DOI":"10.1182\/blood-2011-04-348144","article-title":"TNF\u03b1 facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms","volume":"118","author":"Fleischman","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101385_bb1200","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1182\/blood.2022017326","article-title":"IL-13\/IL-4 signaling contributes to fibrotic progression of the myeloproliferative neoplasms","volume":"140","author":"Melo-Cardenas","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101385_bb1205","doi-asserted-by":"crossref","first-page":"49","DOI":"10.55563\/clinexprheumatol\/ddxmp9","article-title":"Myeloid neoplasms and autoimmune diseases: markers of association","volume":"40","author":"Galimberti","year":"2022","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.blre.2026.101385_bb1210","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.ccr.2011.07.016","article-title":"Rho kinase regulates the survival and transformation of cells bearing oncogenic forms of KIT, FLT3, and BCR-ABL","volume":"20","author":"Mali","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.blre.2026.101385_bb1215","doi-asserted-by":"crossref","first-page":"16636","DOI":"10.1038\/s41598-018-35109-9","article-title":"ROCK2, but not ROCK1 interacts with phosphorylated STAT3 and co-occupies TH17\/TFH gene promoters in TH17-activated human T cells","volume":"8","author":"Chen","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.blre.2026.101385_bb1220","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.12203","article-title":"Rho-associated kinase (ROCK) function is essential for cell cycle progression, senescence and tumorigenesis","volume":"5","author":"K\u00fcmper","year":"2016","journal-title":"Elife"},{"key":"10.1016\/j.blre.2026.101385_bb1225","doi-asserted-by":"crossref","first-page":"1338178","DOI":"10.3389\/fimmu.2024.1338178","article-title":"The impact of gut microbial signals on hematopoietic stem cells and the bone marrow microenvironment","volume":"15","author":"Liu","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.blre.2026.101385_bb1230","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1093\/jac\/dkw062","article-title":"High incidence of neutropenia in patients with prolonged ceftaroline exposure","volume":"71","author":"Furtek","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.blre.2026.101385_bb1235","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/INF.0000000000001716","article-title":"Safety of Outpatient Parenteral Antimicrobial Therapy in Children","volume":"37","author":"Fernandes","year":"2018","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.blre.2026.101385_bb1240","doi-asserted-by":"crossref","first-page":"3326","DOI":"10.1182\/bloodadvances.2022008555","article-title":"The gut microbiota in patients with polycythemia vera is distinct from that of healthy controls and varies by treatment","volume":"7","author":"Eickhardt-Dalb\u00f8ge","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2026.101385_bb1245","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.00662-23","article-title":"Pronounced gut microbiota signatures in patients with JAK2V617F-positive essential thrombocythemia","volume":"11","author":"Eickhardt-Dalb\u00f8ge","year":"2023","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.blre.2026.101385_bb1250","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.597966","article-title":"Intestinal Microbes in Autoimmune and Inflammatory Disease","volume":"11","author":"Wu","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.blre.2026.101385_bb1255","doi-asserted-by":"crossref","DOI":"10.1016\/j.micpath.2020.104344","article-title":"The critical role of Faecalibacterium prausnitzii in human health: An overview","volume":"149","author":"Leylabadlo","year":"2020","journal-title":"Microb Pathog"},{"key":"10.1016\/j.blre.2026.101385_bb1260","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/1753-0407.12986","article-title":"Faecalibacterium prausnitzii-derived microbial anti-inflammatory molecule regulates intestinal integrity in diabetes mellitus mice via modulating tight junction protein expression","volume":"12","author":"Xu","year":"2020","journal-title":"J Diabetes"},{"key":"10.1016\/j.blre.2026.101385_bb1265","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1038\/s41467-022-30240-8","article-title":"Gut microbiota regulates acute myeloid leukaemia via alteration of intestinal barrier function mediated by butyrate","volume":"13","author":"Wang","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.blre.2026.101385_bb1270","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1182\/blood.2021011570","article-title":"IL-1 mediates microbiome-induced inflammaging of hematopoietic stem cells in mice","volume":"139","author":"Kovtonyuk","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101385_bb1275","doi-asserted-by":"crossref","first-page":"3907","DOI":"10.1200\/JCO.2011.36.0792","article-title":"Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980","volume":"29","author":"Kiladjian","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2026.101385_bb1280","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.beha.2014.07.003","article-title":"Leukemic transformation in myeloproliferative neoplasms: therapy-related or unrelated?","volume":"27","author":"Bj\u00f6rkholm","year":"2014","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.blre.2026.101385_bb1285","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/nature13968","article-title":"Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia","volume":"518","author":"Wong","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.blre.2026.101385_bb1290","doi-asserted-by":"crossref","first-page":"e366","DOI":"10.1038\/bcj.2015.95","article-title":"Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors","volume":"5","author":"Cerquozzi","year":"2015","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.blre.2026.101385_bb1295","doi-asserted-by":"crossref","first-page":"615","DOI":"10.2217\/14622416.6.6.615","article-title":"Genetic susceptibility to iatrogenic malignancy","volume":"6","author":"Allan","year":"2005","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.blre.2026.101385_bb1300","first-page":"12","article-title":"Therapy-Related Myeloid Neoplasm: Biology and Mechanistic Aspects of Malignant Progression","author":"Travaglini","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.blre.2026.101385_bb1305","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.cbi.2009.12.013","article-title":"Incidence and susceptibility to therapy-related myeloid neoplasms","volume":"184","author":"Leone","year":"2010","journal-title":"Chem Biol Interact"},{"key":"10.1016\/j.blre.2026.101385_bb1310","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.1038\/s41375-021-01246-w","article-title":"Targeted gene panels identify a high frequency of pathogenic germline variants in patients diagnosed with a hematological malignancy and at least one other independent cancer","volume":"35","author":"Singhal","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2026.101385_bb1315","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2015.44","article-title":"Fanconi anemia gene variants in therapy-related myeloid neoplasms","volume":"5","author":"Voso","year":"2015","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.blre.2026.101385_bb1320","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1136\/jmedgenet-2011-100674","article-title":"Germline mutations in the DNA damage response genes BRCA1, BRCA2, BARD1 and TP53 in patients with therapy related myeloid neoplasms","volume":"49","author":"Schulz","year":"2012","journal-title":"J Med Genet"},{"key":"10.1016\/j.blre.2026.101385_bb1325","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/cncr.29615","article-title":"Inherited mutations in cancer susceptibility genes are common among survivors of breast cancer who develop therapy-related leukemia","volume":"122","author":"Churpek","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.blre.2026.101385_bb1330","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1667\/RR2892.1","article-title":"The incidence of leukemia, lymphoma and multiple myeloma among atomic bomb survivors: 1950-2001","volume":"179","author":"Hsu","year":"2013","journal-title":"Radiat Res"},{"key":"10.1016\/j.blre.2026.101385_bb1335","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1667\/RR15358.1","article-title":"Risk of Leukemia Associated with Protracted Low-Dose Radiation Exposure: Updated Results from the National Registry for Radiation Workers Study","volume":"192","author":"Gillies","year":"2019","journal-title":"Radiat Res"},{"key":"10.1016\/j.blre.2026.101385_bb1340","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2022.101017","article-title":"Radiation and leukaemia: Which leukaemias and what doses?","volume":"58","author":"Gale","year":"2023","journal-title":"Blood Rev"},{"key":"10.1016\/j.blre.2026.101385_bb1345","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/ajh.25307","article-title":"Characteristics of myeloproliferative neoplasms in patients exposed to ionizing radiation following the Chernobyl nuclear accident","volume":"94","author":"Poluben","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2026.101385_bb1350","series-title":"Effects of radiation therapy on clonal hematopoiesis","author":"Modlin","year":"2020"},{"key":"10.1016\/j.blre.2026.101385_bb1355","doi-asserted-by":"crossref","first-page":"17276","DOI":"10.1038\/s41598-022-21621-6","article-title":"Massive expansion of multiple clones in the mouse hematopoietic system long after whole-body X-irradiation","volume":"12","author":"Yoshida","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.blre.2026.101385_bb1360","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijrobp.2022.07.1798","article-title":"Radiation Therapy and Subsequent Clonal Hematopoiesis: An Analysis of a Biorepository of 89,782 Patients","volume":"114","author":"Crants","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.blre.2026.101385_bb1365","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.stem.2019.06.011","article-title":"Outcompeting p53-Mutant Cells in the Normal Esophagus by Redox Manipulation","volume":"25","author":"Fernandez-Antoran","year":"2019","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.blre.2026.101385_bb1370","series-title":"Sources, Effects and Risks of Ionizing Radiation: UNSCEAR 2020\/2021 Report to the General Assembly, with Scientific Annexes","article-title":"United Nations Scientific Committee on the Effects of Atomic Radiation (UNSCEAR)","year":"2021"},{"key":"10.1016\/j.blre.2026.101385_bb1375","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s12929-019-0533-x","article-title":"Basics and applications of tumor-derived extracellular vesicles","volume":"26","author":"Tai","year":"2019","journal-title":"J Biomed Sci"},{"key":"10.1016\/j.blre.2026.101385_bb1380","first-page":"10","article-title":"The Power of Extracellular Vesicles in Myeloproliferative Neoplasms: \u201cCrafting\u201d a Microenvironment That Matters","author":"Catani","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.blre.2026.101385_bb1385","first-page":"24","article-title":"The miRNA Content of Bone Marrow-Derived Extracellular Vesicles Contributes to Protein Pathway Alterations Involved in Ionising Radiation-Induced Bystander Responses","author":"Csord\u00e1s","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.blre.2026.101385_bb1390","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1080\/09553002.2018.1450533","article-title":"Extracellular vesicles mediate low dose ionizing radiation-induced immune and inflammatory responses in the blood","volume":"95","author":"Szatm\u00e1ri","year":"2019","journal-title":"Int J Radiat Biol"},{"key":"10.1016\/j.blre.2026.101385_bb1395","first-page":"11","article-title":"Extracellular Vesicles Derived from Bone Marrow in an Early Stage of Ionizing Radiation Damage Are Able to Induce Bystander Responses in the Bone Marrow","author":"Kis","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.blre.2026.101385_bb1400","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41467-019-13892-x","article-title":"Single-cell analysis based dissection of clonality in myelofibrosis","volume":"11","author":"Mylonas","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.blre.2026.101385_bb1405","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1182\/blood-2017-05-783225","article-title":"Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation","volume":"130","author":"Newberry","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101385_bb1410","doi-asserted-by":"crossref","first-page":"6270","DOI":"10.1038\/s41467-025-60884-1","article-title":"JAK2 inhibition mediates clonal selection of RAS pathway mutations in myeloproliferative neoplasms","volume":"16","author":"Maslah","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.blre.2026.101385_bb1415","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/leu.2017.230","article-title":"Low-burden TP53 mutations in chronic phase of myeloproliferative neoplasms: association with age, hydroxyurea administration, disease type and JAK2 mutational status","volume":"32","author":"Kubesova","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2026.101385_bb1420","doi-asserted-by":"crossref","first-page":"3692","DOI":"10.1182\/blood-2012-05-432989","article-title":"Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-\u03b1 in a murine model of polycythemia vera","volume":"121","author":"Mullally","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101385_bb1425","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1182\/blood.2020005563","article-title":"JAK2-V617F and interferon-\u03b1 induce megakaryocyte-biased stem cells characterized by decreased long-term functionality","volume":"137","author":"Rao","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101385_bb1430","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1182\/bloodadvances.2021004856","article-title":"Genomic profiling of a randomized trial of interferon-\u03b1 vs hydroxyurea in MPN reveals mutation-specific responses","volume":"6","author":"Knudsen","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2026.101385_bb1435","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1182\/blood.2024027528","article-title":"DNMT3A mutations are unlikely to affect interferon alfa treatment outcomes in patients with polycythemia vera","volume":"146","author":"Abu-Zeinah","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101385_bb1440","doi-asserted-by":"crossref","first-page":"e196","DOI":"10.1016\/S2352-3026(19)30236-4","article-title":"Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study","volume":"7","author":"Gisslinger","year":"2020","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.blre.2026.101385_bb1445","doi-asserted-by":"crossref","first-page":"6570","DOI":"10.1182\/blood-2024-211716","article-title":"Prospective Ropeginterferon Alfa-2b Therapy in PV & ET Influences Prothrombotic, Inflammatory and Hypoxia Inducible Factors Activities and Effect of Concomitant DNMT3A Mutation","volume":"144","author":"Song","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101385_bb1450","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1038\/s41375-018-0295-6","article-title":"JAK2V617F but not CALR mutations confer increased molecular responses to interferon-\u03b1 via JAK1\/STAT1 activation","volume":"33","author":"Czech","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2026.101385_bb1455","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1182\/blood.2021010986","article-title":"Inferring the dynamics of mutated hematopoietic stem and progenitor cells induced by IFN\u03b1 in myeloproliferative neoplasms","volume":"138","author":"Mosca","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101385_bb1460","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1038\/leu.2010.120","article-title":"Clonal analysis of erythroid progenitors suggests that pegylated interferon \u03b1-2a treatment targets JAK2V617F clones without affecting TET2 mutant cells","volume":"24","author":"Kiladjian","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2026.101385_bb1465","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1182\/blood-2012-07-442012","article-title":"Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon \u03b1-2a","volume":"122","author":"Quint\u00e1s-Cardama","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101385_bb1470","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1182\/blood-2020-140548","article-title":"Loss of Dnmt3a Confers Resistance to Pegifn\u03b1 in JAK2-V617F Mouse Model","volume":"136","author":"Stetka","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101385_bb1475","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1182\/blood.2020005792","article-title":"Germline genetic factors influence the outcome of interferon-\u03b1 therapy in polycythemia vera","volume":"137","author":"J\u00e4ger","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101385_bb1480","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/s41588-023-01638-x","article-title":"Inherited polygenic effects on common hematological traits influence clonal selection on JAK2(V617F) and the development of myeloproliferative neoplasms","volume":"56","author":"Guo","year":"2024","journal-title":"Nat Genet"},{"key":"10.1016\/j.blre.2026.101385_bb1485","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nrc2676","article-title":"The LKB1-AMPK pathway: metabolism and growth control in tumour suppression","volume":"9","author":"Shackelford","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.blre.2026.101385_bb1490","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1158\/2159-8290.CD-20-1353","article-title":"LKB1\/STK11 Is a Tumor Suppressor in the Progression of Myeloproliferative Neoplasms","volume":"11","author":"Marinaccio","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.blre.2026.101385_bb1495","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1002\/med.21771","article-title":"The role of hypoxia-inducible factor 1 in tumor immune evasion","volume":"41","author":"You","year":"2021","journal-title":"Med Res Rev"},{"key":"10.1016\/j.blre.2026.101385_bb1500","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1182\/blood-2018-06-858597","article-title":"Familial risks of acute myeloid leukemia, myelodysplastic syndromes, and myeloproliferative neoplasms","volume":"132","author":"Sud","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101385_bb1505","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/s41586-020-2786-7","article-title":"Inherited myeloproliferative neoplasm risk affects haematopoietic stem cells","volume":"586","author":"Bao","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.blre.2026.101385_bb1510","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/ng.334","article-title":"JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms","volume":"41","author":"Jones","year":"2009","journal-title":"Nat Genet"},{"key":"10.1016\/j.blre.2026.101385_bb1515","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1182\/blood-2014-01-550863","article-title":"Somatic mutations in calreticulin can be found in pedigrees with familial predisposition to myeloproliferative neoplasms","volume":"123","author":"Lundberg","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101385_bb1520","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/bjh.14041","article-title":"TERT rs2736100 A>C SNP and JAK2 46\/1 haplotype significantly contribute to the occurrence of JAK2 V617F and CALR mutated myeloproliferative neoplasms - a multicentric study on 529 patients","volume":"174","author":"Trifa","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2026.101385_bb1525","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.108458","article-title":"Clonal Hematopoiesis Before, During, and After Human Spaceflight","volume":"33","author":"Mencia-Trinchant","year":"2020","journal-title":"Cell Rep"},{"key":"10.1016\/j.blre.2026.101385_bb1530","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2020.100710","article-title":"Germline genetic factors in the pathogenesis of myeloproliferative neoplasms","volume":"42","author":"Bellann\u00e9-Chantelot","year":"2020","journal-title":"Blood Rev"},{"key":"10.1016\/j.blre.2026.101385_bb1535","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/s41375-018-0281-z","article-title":"Genome-wide association study identifies an acute myeloid leukemia susceptibility locus near BICRA","volume":"33","author":"Walker","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2026.101385_bb1540","doi-asserted-by":"crossref","first-page":"6691","DOI":"10.1038\/ncomms7691","article-title":"Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms","volume":"6","author":"Tapper","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.blre.2026.101385_bb1545","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1182\/blood-2015-06-652941","article-title":"Germ line variants predispose to both JAK2 V617F clonal hematopoiesis and myeloproliferative neoplasms","volume":"128","author":"Hinds","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101385_bb1550","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/s41375-021-01319-w","article-title":"Germline ATG2B\/GSKIP-containing 14q32 duplication predisposes to early clonal hematopoiesis leading to myeloid neoplasms","volume":"36","author":"Pegliasco","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2026.101385_bb1555","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1038\/ng.3380","article-title":"Germline duplication of ATG2B and GSKIP predisposes to familial myeloid malignancies","volume":"47","author":"Saliba","year":"2015","journal-title":"Nat Genet"},{"key":"10.1016\/j.blre.2026.101385_bb1560","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.cell.2023.12.016","article-title":"Inherited blood cancer predisposition through altered transcription elongation","volume":"187","author":"Zhao","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.blre.2026.101385_bb1565","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.70072","article-title":"CHEK2 Germline Variants in Early-Onset and Familial Myeloproliferative Neoplasms","author":"Borsani","year":"2025","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2026.101385_bb1570","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000832","article-title":"Sex Differences in the Spectrum of Clonal Hematopoiesis","volume":"7","author":"Kamphuis","year":"2023","journal-title":"Hemasphere"},{"key":"10.1016\/j.blre.2026.101385_bb1575","first-page":"22","article-title":"Sex-Related Differences in Chronic Myeloid Neoplasms: From the Clinical Observation to the Underlying Biology","author":"Karantanos","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.blre.2026.101385_bb1580","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1111\/bjh.17534","article-title":"Gender-related differences in the outcomes and genomic landscape of patients with myelodysplastic syndrome\/myeloproliferative neoplasm overlap syndromes","volume":"193","author":"Karantanos","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2026.101385_bb1585","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1038\/s41375-020-0935-5","article-title":"Male predominance in AML is associated with specific preleukemic mutations","volume":"35","author":"De-Morgan","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2026.101385_bb1590","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3324\/haematol.2016.149559","article-title":"Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group","volume":"102","author":"Geyer","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2026.101385_bb1595","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.3324\/haematol.2011.045591","article-title":"Disruption of the ASXL1 gene is frequent in primary, post-essential thrombocytosis and post-polycythemia vera myelofibrosis, but not essential thrombocytosis or polycythemia vera: analysis of molecular genetics and clinical phenotypes","volume":"96","author":"Stein","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2026.101385_bb1600","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1182\/bloodadvances.2019001407","article-title":"Sex determines the presentation and outcomes in MPN and is related to sex-specific differences in the mutational burden","volume":"4","author":"Karantanos","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2026.101385_bb1605","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.stem.2018.10.013","article-title":"Inhibition of Inflammatory Signaling in Tet2 Mutant Preleukemic Cells Mitigates Stress-Induced Abnormalities and Clonal Hematopoiesis","volume":"23","author":"Cai","year":"2018","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.blre.2026.101385_bb1610","doi-asserted-by":"crossref","DOI":"10.1172\/JCI140707","article-title":"Hyperglycemia cooperates with Tet2 heterozygosity to induce leukemia driven by proinflammatory cytokine-induced lncRNA Morrbid","volume":"131","author":"Cai","year":"2021","journal-title":"J Clin Invest"},{"key":"10.1016\/j.blre.2026.101385_bb1615","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/j.cell.2021.01.049","article-title":"Increased stem cell proliferation in atherosclerosis accelerates clonal hematopoiesis","volume":"184","author":"Heyde","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.blre.2026.101385_bb1620","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1038\/s41588-022-01121-z","article-title":"Genome-wide analyses of 200,453 individuals yield new insights into the causes and consequences of clonal hematopoiesis","volume":"54","author":"Kar","year":"2022","journal-title":"Nat Genet"},{"key":"10.1016\/j.blre.2026.101385_bb1625","doi-asserted-by":"crossref","DOI":"10.1038\/s41375-024-02298-4","article-title":"Space exploration and cancer: the risks of deeper space adventures","author":"Muhsen","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2026.101385_bb1630","first-page":"364","article-title":"The NASA Twins Study: A multidimensional analysis of a year-long human spaceflight","author":"Garrett-Bakelman","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.blre.2026.101385_bb1635","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/j.stem.2025.07.013","article-title":"Nanobioreactor detection of space-associated hematopoietic stem and progenitor cell aging","volume":"32","author":"Pham","year":"2025","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.blre.2026.101385_bb1640","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.108670","article-title":"Inflammation-driven deaminase deregulation fuels human pre-leukemia stem cell evolution","volume":"34","author":"Jiang","year":"2021","journal-title":"Cell Rep"},{"key":"10.1016\/j.blre.2026.101385_bb1645","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/s42003-022-03777-z","article-title":"Retrospective analysis of somatic mutations and clonal hematopoiesis in astronauts","volume":"5","author":"Brojakowska","year":"2022","journal-title":"Commun Biol"},{"key":"10.1016\/j.blre.2026.101385_bb1650","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1182\/blood-2008-02-138230","article-title":"The natural history and treatment outcome of blast phase BCR-ABL\u2212 myeloproliferative neoplasms","volume":"112","author":"Tam","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101385_bb1655","first-page":"12","article-title":"Myelomonocytic Skewing In Vitro Discriminates Subgroups of Patients with Myelofibrosis with A Different Phenotype, A Different Mutational Profile and Different Prognosis","author":"Geissler","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.blre.2026.101385_bb1660","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.mayocp.2018.08.022","article-title":"3023 Mayo Clinic Patients With Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups","volume":"94","author":"Szuber","year":"2019","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.blre.2026.101385_bb1665","first-page":"124","article-title":"Acute transformation in nonleukemic chronic myeloproliferative disorders: actuarial probability and main characteristics in a series of 218 patients","volume":"85","author":"Cervantes","year":"1991","journal-title":"Acta Haematol"},{"key":"10.1016\/j.blre.2026.101385_bb1670","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1200\/JCO.2010.32.2446","article-title":"DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status","volume":"29","author":"Gangat","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2026.101385_bb1675","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41408-021-00425-3","article-title":"Acute myeloid leukemia: current progress and future directions","volume":"11","author":"Kantarjian","year":"2021","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.blre.2026.101385_bb1680","first-page":"20","article-title":"Blast Transformation in Myeloproliferative Neoplasms: Risk Factors, Biological Findings, and Targeted Therapeutic Options","author":"Iurlo","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.blre.2026.101385_bb1685","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1002\/ajh.23309","article-title":"Clinical significance of genetic aberrations in secondary acute myeloid leukemia","volume":"87","author":"Milosevic","year":"2012","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2026.101385_bb1690","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.3324\/haematol.2016.152363","article-title":"Genomic analysis of myeloproliferative neoplasms in chronic and acute phases","volume":"102","author":"Courtier","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2026.101385_bb1695","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1038\/s41588-025-02190-6","article-title":"Chromothripsis-associated chromosome 21 amplification orchestrates transformation to blast-phase MPN through targetable overexpression of DYRK1A","volume":"57","author":"Brierley","year":"2025","journal-title":"Nat Genet"},{"key":"10.1016\/j.blre.2026.101385_bb1700","doi-asserted-by":"crossref","first-page":"4622","DOI":"10.1038\/s41467-022-32103-8","article-title":"Unified classification and risk-stratification in Acute Myeloid Leukemia","volume":"13","author":"Tazi","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.blre.2026.101385_bb1705","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","article-title":"Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia","volume":"368","author":"Ley","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2026.101385_bb1710","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1038\/s41375-018-0035-y","article-title":"Chromothripsis in acute myeloid leukemia: biological features and impact on survival","volume":"32","author":"Fontana","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2026.101385_bb1715","doi-asserted-by":"crossref","first-page":"3581","DOI":"10.1182\/bloodadvances.2018024018","article-title":"Advanced forms of MPNs are accompanied by chromosomal abnormalities that lead to dysregulation of TP53","volume":"2","author":"Marcellino","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2026.101385_bb1720","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1182\/blood-2009-07-235119","article-title":"Prevalence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosome-negative myeloproliferative neoplasms","volume":"115","author":"Thoennissen","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101385_bb1725","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/ijlh.12257","article-title":"Genomic aberrations of myeloproliferative and myelodysplastic\/myeloproliferative neoplasms in chronic phase and during disease progression","volume":"37","author":"Hahm","year":"2015","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.blre.2026.101385_bb1730","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1002\/ajh.22166","article-title":"Identification of genomic aberrations associated with disease transformation by means of high-resolution SNP array analysis in patients with myeloproliferative neoplasm","volume":"86","author":"Rumi","year":"2011","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2026.101385_bb1735","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/s41408-023-00878-8","article-title":"Blast phase myeloproliferative neoplasm: contemporary review and 2024 treatment algorithm","volume":"13","author":"Tefferi","year":"2023","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.blre.2026.101385_bb1740","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.beha.2019.02.004","article-title":"Therapy-associated leukemic transformation in myeloproliferative neoplasms - What do we know?","volume":"32","author":"Cuthbert","year":"2019","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.blre.2026.101385_bb1745","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1080\/10428194.2018.1441408","article-title":"Outcome of Ph negative myeloproliferative neoplasms transforming to accelerated or leukemic phase","volume":"59","author":"Mollard","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2026.101385_bb1750","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1182\/blood-2004-07-2864","article-title":"Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases","volume":"105","author":"Mesa","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101385_bb1755","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1182\/bloodadvances.2018024422","article-title":"RUNX1 mutations enhance self-renewal and block granulocytic differentiation in human in vitro models and primary AMLs","volume":"3","author":"Gerritsen","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2026.101385_bb1760","doi-asserted-by":"crossref","first-page":"3630","DOI":"10.1182\/blood.2021014465","article-title":"BMP2\/SMAD pathway activation in JAK2\/p53-mutant megakaryocyte\/erythroid progenitors promotes leukemic transformation","volume":"139","author":"Li","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101385_bb1765","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1182\/blood-2021-150191","article-title":"Single-Cell Multi-Omics Reveals the Genetic, Cellular and Molecular Landscape of TP53 Mutated Leukemic Transformation in MPN","volume":"138","author":"Rodriguez-Meira","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101385_bb1770","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1182\/blood-2006-12-062125","article-title":"Leukemic blasts in transformed JAK2-V617F\u2013positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation","volume":"110","author":"Theocharides","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101385_bb1775","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1182\/blood-2009-08-236596","article-title":"Two routes to leukemic transformation after a JAK2 mutation\u2013positive myeloproliferative neoplasm","volume":"115","author":"Beer","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101385_bb1780","doi-asserted-by":"crossref","first-page":"5327","DOI":"10.1038\/s41467-020-19119-8","article-title":"Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics","volume":"11","author":"Morita","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.blre.2026.101385_bb1785","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s40164-024-00479-6","article-title":"Decoding leukemia at the single-cell level: clonal architecture, classification, microenvironment, and drug resistance","volume":"13","author":"Liu","year":"2024","journal-title":"Exp Hematol Oncol"},{"key":"10.1016\/j.blre.2026.101385_bb1790","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1182\/blood.2022016889","article-title":"FLT3ITD drives context-specific changes in cell identity and variable interferon dependence during AML initiation","volume":"141","author":"Li","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101385_bb1795","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/s41591-018-0267-4","article-title":"Myelodysplastic syndrome progression to acute myeloid leukemia at the stem cell level","volume":"25","author":"Chen","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.blre.2026.101385_bb1800","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1158\/2159-8290.CD-18-1453","article-title":"Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia","volume":"9","author":"McMahon","year":"2019","journal-title":"Cancer Discov"},{"key":"10.1016\/j.blre.2026.101385_bb1805","first-page":"86","article-title":"Measurable residual disease in hematologic malignancies: a biomarker in search of a standard","author":"Chandhok","year":"2025","journal-title":"eClinicalMedicine"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X2600024X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X2600024X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:12:56Z","timestamp":1788221576000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X2600024X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":361,"alternative-id":["S0268960X2600024X"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2026.101385","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ph-chromosome-negative myeloproliferative neoplasms: clonal dynamics are the name of the game","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2026.101385","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101385"}}